Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Buprenorphine may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Bunov contain the active ingredient buprenorphine which belongs to a group of medicines called strong analgesics or 'painkillers'. They have been prescribed for you by your doctor to relieve moderate, long-lasting pain that requires the use of a strong painkiller. Bunov should not be used to relieve acute pain. Bunov patches act through the skin. After application, buprenorphine passes through the skin into the blood. Each patch lasts for seven days. 2.
e Bunov
Do not use Bunov: if you are allergic to buprenorphine or any of the other ingredients of this medicine (listed in section 6); if you have breathing problems; if you are addicted to drugs; if you are taking a type of medicine known as a monoamine oxidase inhibitor (examples include tranylcypromine, phenelzine, isocarboxazid, moclobemide and linezolid), or you have taken this type of medicine in the last two weeks; if you suffer from myasthenia gravis (a condition in which the muscles become weak); if you have previously suffered from withdrawal symptoms such as agitation, anxiety, shaking
–
or sweating upon stopping taking alcohol. if you have pain which lasts only for a short period or pain after having an operation because of the increased risk of dependence and developing serious breathing problems. If you are going to have an operation, or have just had an operation, please tell the doctor at the hospital if you are currently treated with Bunov transdermal patch to discuss your pain management.
Bunov must not be used to treat symptoms associated with drug withdrawal. Warnings and precautions Talk to your doctor, pharmacist or nurse before using Bunov: if you are treated with antidepressants. The use of these medicines together with Bunov can lead to serotonin syndrome, a potentially life-threatening condition (see "Other medicines and Bunov"); if you suffer from seizures, fits or convulsions; if you suffer from a breathing related sleep disorder (sleep apnoea); if you have a severe headache or feel sick due to a head injury or increased pressure in your skull (for instance due to brain disease). This is because the patches may make symptoms worse or hide the extent of a head injury; if you are feeling light-headed or faint; if you have severe liver problems; if you or anyone in your family have ever abused or been dependent on alcohol, prescription medicines or illegal drugs ("addiction"); if you are a smoker; if you have ever had problems with your mood (depression, anxiety or a personality disorder) or have been treated by a psychiatrist for other mental illnesses; if you have a high temperature, as this may lead to larger quantities of the active ingredient being absorbed into the blood than normal. if you suffer from constipation. Tolerance, dependence, and addiction This medicine contains buprenorphine which is an opioid medicine. Repeated use of opioids can result in the drug being less effective (you become accustomed to it, known as tolerance). Repeated use of Bunov can also lead to dependence, abuse, and addiction, which may result in lifethreatening overdose. The risk of these side effects can increase with a higher dose and longer duration of use. Dependence or addiction can make you feel that you are no longer in control of how much medicine you need to take or how often you need to take it. The risk of becoming dependent or addicted varies from person to person. You may have a greater risk of becoming dependent on or addicted to Bunov if:
–
Anti-depressants such as moclobemide, tranylcypromine, citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, amitriptyline, doxepine, or trimipramine. These medicines may interact with Bunov and you may experience symptoms such as involuntary, rhythmic contractions of muscles, including the muscles that control movement of the eye, agitation, hallucinations, coma, excessive sweating, tremor, exaggeration of reflexes, increased muscle tension, body temperature above 38°C. Contact your doctor when experiencing such symptoms. Bunov must not be used together with a type of medicine known as a monoamine oxidase inhibitor (examples include tranylcypromine, phenelzine, isocarboxazid, moclobemide and linezolid), or if you have taken this type of medicine in the last two weeks.
–
If you take some medicines such as phenobarbital or phenytoin (medicines commonly used to treat seizures, fits or convulsions), carbamazepine (a medicine to treat seizures, fits or convulsions and certain pain conditions), or rifampicin (a medicine to treat tuberculosis) the effects of Bunov may be reduced. Bunov may make some people feel drowsy, sick or faint or make them breathe more slowly or weakly. These side effects may be made worse if other medicines that produce the same effects are taken at the same time. These include certain medicines to treat pain, depression, anxiety, psychiatric or mental disorders, medicines to help you sleep, medicines to treat high blood pressure such as clonidine, other opioids (which may be found in painkillers or certain cough mixtures e.g. morphine, dextropropoxyphene, codeine, dextromethorphan, noscapine), antihistamines which make you drowsy, or anaesthetics such as halothane.
Concomitant use of Bunov and sedative medicines such as benzodiazepines or related drugs may increase the risk of drowsiness, difficulties in breathing (respiratory depression), coma and may be life-threatening. Because of this, concomitant use should only be considered when other treatment options are not possible. However if your doctor does prescribe Bunov together with sedative medicines the dose and duration of concomitant treatment should be limited by your doctor. Please tell your doctor about all sedative medicines you are taking, and follow your doctor's dose recommendation closely. It could be helpful to inform friends or relatives to be aware of the signs and symptoms stated above. Contact your doctor when experiencing such symptoms. Bunov with food, drink and alcohol Alcohol may make some of the side effects worse and you may feel unwell if you drink alcohol whilst wearing Bunov. Drinking alcohol whilst using Bunov may also affect your reaction time. Pregnancy, breast-feeding and fertility You should not use Bunov if you are pregnant or are breast-feeding, think you may be pregnant or are planning to have a baby, unless otherwise instructed by your doctor having carefully considered the benefits and risk to both the mother and the child. Ask your doctor or pharmacist for advice before taking this medicine. Driving and using machines Bunov may affect your reactions to such an extent that you may not react adequately or quickly enough in the event of unexpected or sudden occurrences. This applies particularly: at the beginning of treatment; if you are taking medicines to treat anxiety or help you sleep; if your dose is increased. Bunov can affect your ability to drive as it may make you sleepy or dizzy.
Bunov
Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Before starting treatment and regularly during treatment, your doctor will discuss with you what you may expect from using Bunov, when and how long you need to take it, when to contact your doctor, and when you need to stop it (see also, If you stop taking Bunov). Different strengths of Bunov are available. Your doctor will decide which strength of Bunov will suit you best. When people first start using Bunov, they often experience some nausea and vomiting (see section 4). This usually passes after the first week of treatment. It's a good idea to book a follow-up appointment with your doctor a week or two after you first start using Bunov patches to ensure that you are taking the correct dose and to manage any side effects. During treatment, your doctor may change the patch you use to a smaller or larger one if necessary, or tell you to use a combination of up to two patches. Do not cut or divide the patch or use a higher dose than recommended. You should not apply more than two patches at the same time, up to a maximum total dose of 40 micrograms/hour. Adults and elderly patients Unless your doctor has told you differently, attach one Bunov patch (as described in detail below) and change it every seventh day, preferably at the same time of day. Your doctor may wish to adjust the dose after 3-7 days until the correct level of pain control has been found. If your doctor has advised you to take other painkillers in addition to the patch, strictly follow the doctor's instructions, otherwise you will not fully benefit from treatment with Bunov. The patch should be worn for 3 full days before increasing the dose, this is when the maximum effect of a given dose is established. Patients with kidney disease/dialysis patients In patients with kidney disease, no change in dose is necessary. Patients with liver disease In patients with liver disease, the effects and period of action of the Bunov may be affected and your doctor will therefore check on you more closely. Patients under 18 years of age Bunov should not be used in patients below the age of 18 years. Method of administration Bunov transdermal patch is for transdermal use. Bunov act through the skin. After application, buprenorphine passes through the skin into the blood. Before applying the transdermal patch
–
Choose an area of nonirritated, intact skin on your upper arm, outer arm, upper chest, upper back or side of the chest. (See illustrations besides). Ask for assistance if you cannot apply the patch yourself.
Upper Arm or
Front
or
Back
or
–
The Bunov patch should be applied to a relatively hairless or nearly hairless skin site. If no suitable hair free sites are available the hairs should be cut off with a pair of scissors. Do not shave them off.
–
Avoid skin which is red, irritated or has any other blemishes, for instance large scars.
–
The area of skin you choose must be dry and clean. If necessary, wash it with cold or lukewarm water. Do not use soap, alcohol, oil, lotions or other detergents. After a hot bath or shower, wait until your skin is completely dry and cool. Do not apply lotion, cream or ointment to the chosen area. This might prevent your patch from sticking properly.
Applying the transdermal patch –
Step 1: Each transdermal patch is sealed in a sachet. Just before use, cut the sachet along the sealed edge with scissors. Take out the transdermal patch. Do not use the patch if the sachet seal is broken.
–
Step 2: The sticky side of the transdermal patch is covered with a transparent protective foil. Carefully peel off one part of the foil. Try not to touch the sticky part of the transdermal patch.
–
Step 3: Stick the transdermal patch on to the area of skin you have chosen and remove the remaining foil.
–
Step 4: Press the transdermal patch against your skin with the palm of your hand and count slowly to 30. Make sure that the whole transdermal patch is in contact with your skin, especially at the edges.
Wearing the transdermal patch You should wear the patch for seven days. Provided that you have applied the patch correctly, there is little risk of it coming off. If the edges of the patch begin to peel off, they may be taped down with a suitable skin tape. You may shower, bathe or swim whilst wearing it. Do not expose the patch to extreme heat (e.g. heating pads, electric blanket, heat lamps, sauna, hot tubs, heated water beds, hot water bottle, etc) as this may lead to larger quantities of the active ingredient being absorbed into the blood than normal. External heat may also prevent the patch from sticking properly. If you have a high temperature this may alter the effects of Bunov (see "Warnings and precautions" section above).
In the unlikely event that your patch falls off before it needs changing, do not use the same patch again. Stick a new one on straight away (see "Changing the transdermal patch" below). Changing the transdermal patch –
Take the old transdermal patch off. Fold it in half with the sticky side inwards. Open and take out a new patch. Use the empty sachet to dispose of the old patch. Now discard the sachet safely. Even used patches contain some active ingredient that may harm children or animals, so make sure your used patches are always kept out of the reach and sight of them. Stick a new transdermal patch on a different appropriate skin site (as described above). You should not apply a new patch to the same site for 3-4 weeks. Remember to change your patch at the same time of day. It is important that you make a note of the time of day.
Duration of treatment Your doctor will tell you how long you should be treated with the Bunov. Do not stop treatment without consulting a doctor, because your pain may return and you may feel unwell (see also "If you stop using Bunov" below). If you feel that the effect of the Bunov is too weak or too strong, talk to your doctor or pharmacist. If you use more Bunov than you should As soon as you discover that you have used more patches than you should, remove all patches and call your doctor or hospital straight away. People who have taken an overdose may feel very sleepy and sick. They may also have breathing difficulties or lose consciousness and may need emergency treatment in hospital. When seeking medical attention make sure that you take this leaflet and any remaining patches with you to show to the doctor. If you forget to use Bunov Stick a new patch on as soon as you remember. Also make a note of the date, as your usual day of changing may now be different. If you are very late changing your patch, your pain may return. In this case, please contact your doctor. Do not apply additional patches to make up for the forgotten application. If you stop using Bunov If you stop using Bunov too soon or you interrupt your treatment your pain may return. If you wish to stop treatment please consult your doctor. They will tell you what can be done and whether you can be treated with other medicines. Some people may have side effects when they have used strong painkillers for a long time and stop using them. The risk of having effects after stopping Bunov is very low. However, if you feel agitated, anxious, nervous or shaky, if you are overactive, have difficulty sleeping or digestive problems, tell your doctor. The pain relieving effect of Bunov is maintained for some time after removal of the patch. You should not start another opioid analgesic (strong painkiller) within 24 hours after removal of the patch. If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 4.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects that may be associated with Bunov are similar to those seen with other strong painkillers and include difficulty in breathing and low blood pressure. This medicine can cause allergic reactions, although serious allergic reactions are rare. Remove the patch and tell your doctor immediately if you get any sudden wheeziness, difficulties in breathing, swelling of the eyelids, face or lips, rash or itching especially those covering your whole body. As with all strong painkillers, there is a risk that you may become addicted or reliant on Bunov. In patients treated with buprenorphines, the following other side effects have been reported: Very common (may affect more than 1 in 10 people):
• • • • • •
Local allergic reaction with marked signs of swelling (in such cases treatment should be stopped). Swelling and irritation inside the nose. Decreased erection, sexual dysfunction. A flu like illness. Flushing of the skin. Dehydration.
Very rare (may affect up to 1 in 10,000 people):
Bunov
•
Keep this medicine out of the sight and reach of children.
•
Store this medicine in a safe and secure place, where other people cannot access it. It can cause serious harm and be fatal to people who may take this medicine by accident, or intentionally when it has not been prescribed for them.
•
Do not use this medicine after the expiry date which is stated on the carton and sachet after EXP. The expiry date refers to the last day of that month.
•
[5 microgram/h] & [10 microgram/h]: Do not store above 25°C.
•
[20 microgram/h]: This medicine does not require any special storage conditions.
•
Do not use the patch if the sachet seal is broken.
•
Used patches must be folded over on themselves with the adhesive layer inwards, and discarded safely.
•
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6.
What Bunov patches contain The active substance is buprenorphine. [5 microgram/h:] Each transdermal patch contains 5 mg of buprenorphine in a patch size of 6.25 cm2 and releases 5 micrograms of buprenorphine per hour (over a period of 7 days). [10 microgram/h:] Each transdermal patch contains 10 mg of buprenorphine in a patch size of 12.5 cm2 and releases 10 micrograms of buprenorphine per hour (over a period of 7 days). [20 microgram/h:] Each transdermal patch contains 20 mg of buprenorphine in a patch size of 25 cm2 and releases 20 micrograms of buprenorphine per hour (over a period of 7 days). The other ingredients are: Adhesive matrix (containing buprenorphine): povidone K90, levulinic acid, oleyl oleate, Poly[acrylic acid-co-butylacrylate-co-(2-ethylhexyl)acrylate-co-vinylacetate] (5:15:75:5) Adhesive matrix (without buprenorphine): Poly[(2-ethylhexyl)acrylate-co-glycidylmethacrylateco-(2-hydroxyethyl)acrylate-co-vinylacetate] (68:0,15:5:27), Separating foil between adhesive matrices with and without buprenorphine: Polyethylene terephthalate film, Backing foil: polyester, Release liner: Polyethylene terephthalate film, siliconised Blue printing ink What Bunov look like and contents of the pack Transdermal patch Three sizes are available. [5 microgram/h:] Each transdermal patch is beige coloured with rounded corners and is imprinted with "Buprenorphin" and "5 μg/h" [10 microgram/h:] Each transdermal patch is beige coloured with rounded corners and is imprinted with "Buprenorphin" and "10 μg/h" [20 microgram/h:] Each transdermal patch is beige coloured with rounded corners and is imprinted with "Buprenorphin" and "20 μg/h" One transdermal patch is sealed in one child-resistant sachet. The patches are available in cartons containing 2, 4, 5, 8 or 12 transdermal patches. Not all pack sizes may be marketed. Marketing Authorisation Holder Glenmark Pharmaceuticals Europe Limited Laxmi House
2B Draycott Avenue Kenton, Middlesex HA3 0BU United Kingdom Manufacturer Labtec GmbH Heykenaukamp 10 21147 Hamburg Germany AdhexPharma 42/44 rue de Longvic 21300 Chenôve France This leaflet was last revised in May 2026
Bunov 10 microgram/h transdermal patch comes as patch containing 10mcg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Bunov 10 microgram/h transdermal patch is buprenorphine.
Medicines with the same active substance, strength and form include: BuTrans 10 microgram/hour transdermal patch, Butec 10 microgram/hour transdermal patch, Panitaz 10 micrograms/h Transdermal Patches. In total there are 5 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Bunov 10 microgram/h transdermal patch, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Treatment of non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia.
Bunov is not suitable for the treatment of acute pain.
Bunov is indicated in adults.
Posology
Bunov should be administered every 7th day.
Patients aged 18 years and over:
The lowest Bunov dose (Bunov 5 microgram/hour transdermal patch) should be used as the initial dose. Consideration should be given to the previous opioid history of the patient (see section 4.5) as well as to the current general condition and medical status of the patient.
Titration
During initiation of treatment with Bunov, short-acting supplemental analgesics may be required (see section 4.5) as needed until analgesic efficacy with Bunov is attained.
During the titration process, the dose of Bunov may be adjusted every 3 days (72 hours). Thereafter, the 7-day dosing interval should be maintained. Subsequent dosage increases may then be titrated based on the need for supplemental pain relief and the patient's analgesic response to the patch.
To increase the dose, a larger patch should replace the patch that is currently being worn, or a combination of patches should be applied in different places to achieve the desired dose. It is recommended that no more than two patches are applied at the same time, up to a maximum total dose of 40 microgram/hour buprenorphine. A new patch should not be applied to the same skin site for the subsequent 3-4 weeks (see section 5.2). Patients should be carefully and regularly monitored to assess the optimum dose and duration of treatment.
In the absence of adequate pain control, the possibility of hyperalgesia, tolerance and progression of underlying disease should be considered (see section 4.4). A Bunov dose reduction or discontinuation of Bunov treatment or treatment review may be indicated.
Conversion from opioids
Bunov can be used as an alternative to treatment with other opioids. Such patients should be started on the lowest available dose (Bunov 5 microgram/hour transdermal patch) and continue taking short-acting supplemental analgesics (see section 4.5) during titration, as required.
Elderly
No dosage adjustment of Bunov is required in elderly patients.
Renal impairment
No special dose adjustment of Bunov is necessary in patients with renal impairment.
Hepatic impairment
There is no need for dosage adjustment of Bunov in patients with mild to moderate hepatic impairment. Buprenorphine is metabolised in the liver. The intensity and duration of its action may be affected in patients with impaired liver function. Therefore, such patients should be carefully monitored during treatment with Bunov.
Patients with severe hepatic impairment may accumulate buprenorphine during Bunov treatment. Consideration of alternate therapy should be considered, and Bunov should be used with caution, if at all, in such patients.
Paediatric population
The safety and efficacy of Bunov in children below 18 years of age has not been established. No data are available.
Method of administration
Route of administration
Transdermal patch to be worn for 7 days.
The patch must not be divided or cut into pieces.
The patch should not be used if the seal is broken.
Patch application
In order to ensure effective analgesia of buprenorphine and to minimise the potential of skin reactions (see section 4.4), the following directions of use should be followed:
Bunov should be applied to non-irritated, intact skin of the upper outer arm, upper chest, upper back or the side of the chest, but not to any parts of the skin with large scars. Bunov should be applied to a relatively hairless or nearly hairless skin site. If none are available, the hair at the site should be cut with scissors, not shaven.
If the application site must be cleaned, it should be done with clean water only. Soaps, alcohol, oils, lotions or abrasive devices must not be used. The skin must be dry before the patch is applied. Bunov should be applied immediately after removal from the sealed sachet. Following removal of the protective layer, the transdermal patch should be pressed firmly in place with the palm of the hand for approximately 30 seconds, making sure the contact is complete, especially around the edges. If the edges of the patch begin to peel off, the edges may be taped down with suitable skin tape to ensure a 7 day period of wear. The patch should be worn continuously for 7 days. Bathing, showering, or swimming should not affect the patch. If a patch falls off, a new one should be applied and worn for 7 days.
Treatment goals and discontinuation
Before initiating treatment with Bunov, a treatment strategy including treatment duration and treatment goals, and a plan for end of the treatment, should be agreed together with the patient, in accordance with pain management guidelines. During treatment, there should be frequent contact between the physician and the patient to evaluate the need for continued treatment, consider discontinuation and to adjust dosages if needed. When a patient no longer requires therapy with Bunov, it may be advisable to taper the dose gradually to prevent symptoms of withdrawal. In absence of adequate pain control, the possibility of hyperalgesia, tolerance and progression of underlying disease should be considered (see section 4.4).
Duration of treatment
Bunov should not be used for longer than necessary.
Discontinuation
After removal of the patch, buprenorphine serum concentrations decrease gradually and thus the analgesic effect is maintained for a certain amount of time. This should be considered when therapy with Bunov is to be followed by other opioids. As a general rule, a subsequent opioid should not be administered within 24 hours after removal of the patch. At present, only limited information is available on the starting dose of other opioids administered after discontinuation of the transdermal patch (see section 4.5).
Patients with fever or exposed to external heat:
While wearing the patch, patients should be advised to avoid exposing the application site to external heat sources, such as heating pads, electric blankets, hot water bottles, heat lamps, sauna, hot tubs, and heated water beds, etc., as an increase in absorption of buprenorphine may occur. When treating febrile patients, one should be aware that fever may also increase absorption resulting in increased plasma concentrations of buprenorphine and thereby increased risk of opioid reactions.
Bunov is contraindicated in:
- Patients with known hypersensitivity to the active substance buprenorphine or to any of the excipients (see section 6.1),
- opioid dependent patients and for narcotic withdrawal treatment,
- conditions in which the respiratory centre and function are severely impaired or may become so,
- patients who are receiving MAO inhibitors or have taken them within the last two weeks (see section 4.5)
- patients suffering from myasthenia gravis
- patients suffering from delirium tremens.
Bunov should be used with particular caution in patients with:
- Respiratory depression
- CNS depressants co-administration (see below and section 4.5)
- Serotonergic agents (see below and section 4.5)
- Psychological dependence [addiction], abuse profile and history of substance and/or alcohol abuse (see below)
- Sleep apnoea
- Acute alcohol intoxication,
- Head injury, intracranial lesions or increased intracranial pressure, shock, a reduced level of consciousness of uncertain origin
- Severely impaired hepatic function (see section 4.2)
- Constipation.
Respiratory depression
Significant respiratory depression has been associated with buprenorphine, particularly by the intravenous route. A number of overdose deaths have occurred when addicts have intravenously abused buprenorphine, usually with benzodiazepines concomitantly. Additional overdose deaths due to ethanol and benzodiazepines in combination with buprenorphine have been reported (see section 4.9). Caution should be exercised when prescribing Bunov to patients known to have, or suspected of having, problems with drug or alcohol abuse or serious mental illness.
Concomitant use of Bunov opioids such as Buprenorphine and sedative medicines such as benzodiazepines or related drugs may result in sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing with these sedative medicines should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe buprenorphine concomitantly with sedative medicines, the lowest effective dose should be used, and the duration of treatment should be as short as possible.
The patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their caregivers to be aware of these symptoms (see section 4.5).
Serotonin syndrome
Concomitant administration of Buprenorphine and other serotonergic agents, such as MAO inhibitors, selective serotonin re-uptake inhibitors (SSRIs), serotonin norepinephrine re-uptake inhibitors (SNRIs) or tricyclic antidepressants may result in serotonin syndrome, a potentially life-threatening condition (see section 4.5).
If concomitant treatment with other serotonergic agents is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.
Symptoms of serotonin syndrome may include mental-status changes, autonomic instability, neuromuscular abnormalities, and/or gastrointestinal symptoms.
If serotonin syndrome is suspected, a dose reduction or discontinuation of therapy should be considered depending on the severity of the symptoms.
Buprenorphine is a μ-opioid agonist, acting as a full agonist with respect to analgesia and as a partial agonist with respect to its respiratory depressant properties (see section 5.1).
Long-term treatment effects and tolerance
In all patients, tolerance to the analgesic effects, hyperalgesia, physical dependence, and psychological dependence may develop upon repeated administration of opioids, whereas incomplete tolerance is developed for some side effects like opioid induced constipation. Particularly in patients with chronic non cancer pain, it has been reported that they may not experience a meaningful amelioration in pain intensity from continuous opioid treatment in the long term. It is recommended to re-evaluate the appropriateness of continued use of Bunov regularly at the time of prescription renewals in patients. When it is decided that there is no benefit for continuation, gradual down titration should be applied to address withdrawal symptoms.
Tolerance and opioid use disorder (abuse and dependence)
Tolerance, physical and psychological dependence, and opioid use disorder (OUD) may develop upon repeated administration of opioids such as Bunov. Repeated use of Bunov can lead to OUD. A higher dose and longer duration of opioid treatment can increase the risk of developing OUD. Abuse or intentional misuse of Bunov may result in overdose and/or death. The risk of developing OUD is increased in patients with a personal or a family history (parents or siblings) of substance use disorders (including alcohol use disorder), in current tobacco users or in patients with a personal history of other mental health disorders (eg major depression, anxiety and personality disorders).
Before initiating treatment with Bunov and during the treatment, treatment goals and a discontinuation plan should be agreed with the patient (see section 4.2). Before and during treatment the patient should also be informed about the risks and signs of OUD. If these signs occur, patients should be advised to contact their physician.
Patients will require monitoring for signs of drug-seeking behaviour (e.g. too early requests for refills). This includes the review of concomitant opioids and psycho-active drugs (like benzodiazepines). For patients with signs and symptoms of OUD, consultation with an addiction specialist should be considered.
Withdrawal syndrome
A withdrawal syndrome may occur upon abrupt cessation of therapy. Withdrawal (abstinence syndrome), when it occurs, is generally mild, begins after 2 days and may last up to 2 weeks. Withdrawal symptoms include agitation, anxiety, nervousness, insomnia, hyperkinesia, tremor and gastrointestinal disorders. When a patient no longer requires therapy with buprenorphine, it may be advisable to taper the dose gradually to prevent symptoms of withdrawal. Administration of buprenorphine to persons who are physically dependent on full μ-opioid agonists may precipitate an abstinence syndrome depending on the level of physical dependence, and the timing and dose of buprenorphine.
Sleep-related breathing disorders
Opioids can cause sleep-related breathing disorders including central sleep apnoea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider decreasing the total opioid dosage.
Skin reactions at application site
To minimise the risk of occurrence of application site skin reactions, it is important to follow the posology instructions (see section 4.2).
Application site reactions with Bunov are usually presented by a mild or moderate skin inflammation (contact dermatitis), and their typical appearance may include erythema, oedema, pruritus, rash, small blisters (vesicles), and painful/burning sensation at the application site. Most commonly the cause is skin irritation (irritant contact dermatitis), and these reactions resolve spontaneously after Bunov removal.
Patients and caregivers should be instructed accordingly to monitor the application sites for such reactions. If allergic contact dermatitis is suspected, relevant diagnostic procedures should be performed to determine if sensitisation has occurred and its actual cause (buprenorphine and/or other ingredients of the patch).
Since CYP3A4 inhibitors may increase concentrations of buprenorphine (see section 4.5), patients already treated with CYP3A4 inhibitors should have their dose of Bunov carefully titrated since a reduced dosage might be sufficient in these patients.
Bunov is not recommended for analgesia in the immediate post-operative period. Do not use for acute post-operative pain owing to the increased risk of persistent post-operative opioid use (PPOU) and opioid-induced ventilatory impairment (OIVI) or in other situations characterised by a narrow therapeutic index or a rapidly varying analgesic requirement.
Buprenorphine may lower the seizure threshold in patients with a history of seizure disorder.
Severe febrile illness may increase the rate of buprenorphine absorption from Bunov transdermal patches.
In humans limited euphorigenic effects have been observed with buprenorphine. This may result in some abuse of the product.
Endocrine system
Opioids may influence the hypothalamic-pituitary-adrenal or –gonadal axes. Some changes that can be seen include an increase in serum prolactin, and decreases in plasma cortisol and testosterone. Clinical symptoms may be manifest from these hormonal changes.
Bunov should not be used at higher doses than recommended.
Effect of other active substances on the pharmacokinetics of buprenorphine:
Buprenorphine is primarily metabolised by glucuronidation and to a lesser extent (about 30%) by CYP3A4.
Concomitant treatment with CYP3A4 inhibitors may lead to elevated plasma concentrations with intensified efficacy of buprenorphine.
Studies with the CYP3A4 inhibitor ketoconazole did not produce clinically relevant increases in mean maximum (Cmax) or total (AUC) buprenorphine exposure following buprenorphine with ketoconazole as compared to buprenorphine alone.
The interaction between buprenorphine and CYP3A4 enzyme inducers has not been studied.
Co-administration of buprenorphine and enzyme inducers (e.g. phenobarbital, carbamazepine, phenytoin and rifampicin) could lead to increased clearance which might result in reduced efficacy.
Reductions in hepatic blood flow induced by some general anaesthetics (e.g. halothane) and other medicinal products may result in a decreased rate of hepatic elimination of buprenorphine.
Pharmacodynamic interactions:
Bunov must not be used concomitantly with MAOIs or in patients who have received MAOIs within the previous two weeks (see section 4.3).
Bunov should be used cautiously when co-administered with:
Serotonergic medicinal products, such as MAO inhibitors, selective serotonin re-uptake inhibitors (SSRIs), serotonin norepinephrine re-uptake inhibitors (SNRIs) or tricyclic antidepressants as the risk of serotonin syndrome, a potentially life-threatening condition, is increased (see section 4.4).
Other central nervous system depressants: other opioid derivatives (analgesics and antitussives containing e.g. morphine, dextropropoxyphene, codeine, dextromethorphan or noscapine). Certain antidepressants, sedative H1-receptor antagonists, alcohol, anxiolytics, neuroleptics, clonidine and related substances. These combinations increase the CNS depressant activity.
The concomitant use of Bunov with gabapentinoids (gabapentin and pregabalin) may result in respiratory depression, hypotension, profound sedation, coma or death (see section 4.4).
Concomitant administration of buprenorphine with anticholinergics or medications with anticholinergic activity (e.g. tricyclic antidepressants, antihistamines, antipsychotics, muscle relaxants, anti-Parkinson drugs) may result in increased anticholinergic adverse effects.
Sedative medicines such as benzodiazepines or related drugs as concomitant use increases the risk of sedation, respiratory depression, coma and death because of additive CNS depressant effect. The dose and duration of concomitant use should be limited (see section 4.4). Such agents include sedatives or hypnotics, general anesthetic's, other opioid analgesics, phenothiazines, centrally acting anti-emetics, benzodiazepines and alcohol.
At typical analgesic doses buprenorphine is described to function as a pure mu receptor agonist. In buprenorphine clinical studies subjects receiving full mu agonist opioids (up to 90 mg oral morphine or oral morphine equivalents per day) were transferred to buprenorphine. There were no reports of abstinence syndrome or opioid withdrawal during conversion from entry opioid to buprenorphine (see section 4.4).
Pregnancy
There are no or limited amount of data from the use of buprenorphine in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.
Buprenorphine crosses the placenta and buprenorphine and the active metabolite norbuprenorphine can be detected in newborn serum, urine and meconium following in utero exposure. Towards the end of pregnancy high doses of buprenorphine may induce respiratory depression in the neonate even after a short period of administration. Prolonged use of buprenorphine during pregnancy can result in neonatal opioid withdrawal syndrome.
Therefore Bunov should not be used during pregnancy and in women of childbearing potential who are not using effective contraception unless the potential benefit justifies the potential risk to the foetus.
Breastfeeding
Buprenorphine is excreted in human milk. Studies in rats have shown that buprenorphine may inhibit lactation. Available pharmacodynamic/toxicological data in animals has shown excretion of buprenorphine in milk (see section 5.3). A risk to the newborn/infants cannot be excluded.. Bunov should be used with caution during breast-feeding.
Fertility
No human data on the effect of buprenorphine on fertility are available. In a fertility and early embryonic development study, no effects on reproductive parameters were observed in male or female rats (see section 5.3).
Bunov has a major influence on the ability to drive and use machines. Even when used according to instructions, Bunov may affect the patient's reactions to such an extent that road safety and the ability to operate machinery may be impaired. This applies particularly in the beginning of treatment and in conjunction with other centrally acting substances including alcohol, tranquillisers, sedatives and hypnotics. An individual recommendation should be given by the physician. A general restriction is not necessary in cases where a stable dose is used.
Patients who are affected and experience side effects (e.g. dizziness, drowsiness, blurred vision) during treatment initiation or titration to a higher dose should not drive or use machines, for at least 24 hours after the patch has been removed.
Serious adverse reactions that may be associated with buprenorphine therapy in clinical use are similar to those observed with other opioid analgesics, including respiratory depression (especially when used with other CNS depressants) and hypotension (see section 4.4).
The following undesirable effects have occurred:
Very common (≥1/10), common (≥1/100, <1/10), uncommon (≥1/1000, <1/100), rare (≥1/10,000, <1/1000), very rare (<1/10,000), not known (cannot be estimated from the available data).
System organ class
MedDRA
Very common
(≥1/10)
Common
(≥1/100 to <1/10)
Uncommon
(≥1/1000 to <1/100)
Rare
(≥1/10,000 to <1/1000)
Very rare
(<1/10,000)
Not known (cannot be estimated from the available data)
Immune system disorders
Hypersensitivity
Anaphylactic reaction
Anaphylactoid reaction
Metabolic and nutritional disorders
Anorexia
Dehydration
Psychiatric disorders
Confusion,
Depression,
Insomnia,
Nervousness,
Anxiety
Sleep disorder,
Restlessness,
Agitation,
Euphoric mood,
Affect lability,
Hallucinations,
Aggression,
Nightmares,
Decreased libido
Psychotic disorder
Drug dependence (see section 4.4),
Mood swings
Depersonalisation
Nervous system disorders
Headache,
Dizziness,
Somnolence
Tremor
Sedation,
Dysgeusia,
Dysarthria,
Hypoaesthesia,
Memory impairment,
Migraine,
Syncope,
Abnormal co-ordination,
Disturbance in attention,
Paraestheia
Balance disorder,
Speech disorder
Involuntary muscle contractions
Seizures
Sleep apnoea syndrome
Hyperalgesia
Eye disorders
Dry eye,
Blurred vision
Visual disturbance,
Eyelid oedema,
Miosis
Ear and labyrinth disorders
Tinnitus,
Vertigo
Ear pain
Cardiac disorders
Palpitations,
Tachycardia
Angina pectoris
Vascular disorders
Hypotension,
Circulatory collapse,
Hypertension,
Flushing
Vasodilatation,
Orthostatic hypotension
Respiratory, thoracic and mediastinal disorders
Dyspnoea
Cough,
Wheezing,
Hiccups
Respiratory depression,
Respiratory failure,
Asthma aggravated,
Hyperventilation,
Rhinitis
Gastrointestinal disorders
Constipation,
Nausea,
Vomiting
Abdominal pain,
Diarrhoea,
Dyspepsia,
Dry mouth
Flatulence
Dysphagia,
Ileus
Diverticulitis
Hepatobiliary disorders
Biliary colic
Skin and subcutaneous tissue disorders
Pruritus,
Erythema
Rash,
Sweating,
Exanthema
Dry skin,
Urticaria,
Face oedema
Pustules,
Vesicles
Dermatitis contact,
Application skin discolouration
Musculoskeletal and connective tissue disorders
Muscular weakness
Myalgia,
Muscle spasms
Renal and urinary disorders
Urinary incontinence,
Urinary retention,
Urinary hesitation
Reproductive system and breast disorders
Erectile dysfunction,
Sexual dysfunction
General disorders and administration site conditions
Application site reaction1*
Tiredness,
Asthenic conditions,
Peripheral oedema
Fatigue,
Pyrexia,
Rigors,
Oedema,
Drug withdrawal syndrome,
Chest pain
Influenza like illness
Drug withdrawal syndrome neonatal
Drug tolerance
Investigations
Alanine aminotransferase increased,
Weight decreased
Injury, poisoning and procedural complications
Accidental injury,
Fall
1Includes common signs and symptoms of contact dermatitis (irritative or allergic): erythema, oedema, pruritus, rash, vesicles, painful/burning sensation at the application site.
* In some cases delayed local allergic reactions (allergic contact dermatitis) occurred with marked signs of inflammation. Mechanical injuries during patch removal (e.g. laceration) are also possible in patients with fragile skin. Chronic inflammation may lead to long-lasting sequelae, such as post inflammatory hyper- and hypopigmentation, as well as dry and thick scaly skin lesions, which may closely resemble scars. In such cases treatment with buprenorphine should be terminated (see sections 4.3 and 4.4.
Drug dependence
Repeated use of Bunov can lead to drug dependence, even at therapeutic doses. The risk of drug dependence may vary depending on a patient's individual risk factors, dosage, and duration of opioid treatment (see section 4.4).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard
Symptoms: Symptoms similar to those of other centrally acting analgesics are to be expected. These may include respiratory depression, including apnoea, sedation, drowsiness, nausea, vomiting, cardiovascular collapse and marked miosis.
Treatment: Remove any patches from the patient's skin. Establish and maintain a patent airway, assist or control respiration as indicated and maintain adequate body temperature and fluid balance. Oxygen, intravenous fluids, vasopressors and other supportive measures should be employed as indicated.
A specific opioid antagonist such as naloxone may reverse the effects of buprenorphine, although naloxone may be less effective in reversing the effects of buprenorphine than other µ-opioid agonists. Treatment with continuous intravenous naloxone should begin with the usual doses but high doses may be required.
Ask anything about Bunov 10 microgram/h transdermal patch. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.